ライフサイエンスコーパス: body weight loss

1 on with no observed toxicities as defined by body weight loss.

2 duction in 24 h food intake with concomitant body weight loss.

3 toxicity was assessed in rats as measured by body weight loss.

4 ts, rather, treated mice suffered tremendous body weight loss.

5 t efficacy in a TNBC xenograft model without body weight loss.

6 ppress disease, as it is manifested by total body weight loss.

7 est systemic toxicity as reflected in animal body weight loss.

8 ays postimplantation, with negligible animal body weight loss.

9 and body weight gain or decreased intake and body weight loss.

10 week) was determined by efficacy and minimal body weight loss.

11 evere metabolic changes, anorexia, and rapid body weight loss.

12 ling mediates cisplatin-induced anorexia and body weight loss.

13 nd evidence included temperature changes and body weight loss.

14 with reduced bacterial clearance and greater body weight loss.

15 ter challenge model, reducing viral load and body weight loss.

16 signs of systemic toxicity and only limited body weight loss.

17 ntify variables associated with >5% of total body weight loss.

18 e of safely achieving sizeable and sustained body weight loss.

19 improves glucose tolerance independently of body weight loss.

20 n dosed iv in a TNBC xenograft model without body weight loss.

21 e dual agonist's efficacy on food intake and body weight loss.

22 sistant to chemotherapy-induced anorexia and body weight loss.

23 le TNBC xenograft models without significant body weight loss.

24 otor performance, accompanied by progressive body weight loss.

25 severity, as assessed by striatal volume and body weight loss.

26 the humane endpoint, which was due to rapid body weight loss.

27 ted viral infection-induced liver injury and body weight loss.

28 icacy but worsened survival due to excessive body weight loss.

29 of cisplatin-induced malaise, anorexia, and body weight loss.

30 allenge, though they experienced viremia and body weight loss.

31 orticosterone, reduction of food intake, and body weight loss.

32 id extractable Ba were linearly related to % body weight loss.

33 ase parasite burden, but it had no effect on body weight loss.

34 eated with mP-PTX had no obvious ascites and body-weight loss.

35 r of therapy and maintained a 20.1% +/- 3.5% body weight loss (54.6% +/- 12.0% of EWL).

36 spendthrift" metabolic phenotypes related to body weight loss 6 mo later.

37 performance quartiles when comparing excess body weight loss (67.2% vs 68.5%; P = .86) at 1 year.

38 se-dependent reduction in viral replication, body weight loss, acute lung injury, and pulmonary funct

39 fer with respect to sex, age, BMI, and total body weight loss after RYGB.

40 Women who achieved a > or =50% excess body weight loss after surgery were asked to complete th

41 ften surpass the expected improvement due to body weight loss alone.

42 d whether food restriction in the absence of body weight loss alters drug reward sensitivity.

43 l or control treatment that (1) RYGB-induced body weight loss and (2) the satiating efficacy of endog

44 en allowed to recover had significantly less body weight loss and a decrease in histologic injury ver

45 tabolic disruption that leads to involuntary body weight loss and accelerated mortality in affected p

46 itamin D analog paricalcitol prevented mouse body weight loss and alleviated lung fibrosis, whereas v

47 IL-1 of corticosterone and IL-6, and causes body weight loss and B cell hyperplasia with serum IgG a

48 ving the disease activity index and reducing body weight loss and colonic tissue damage.

49 reatment-induced toxicity was quantified via body weight loss and complete blood count.

50 tiated early after lethal infection hampered body weight loss and completely protected mice from leth

51 in knockout mice does not protect them from body weight loss and death upon infection with H3N2 infl

52 The body weight loss and disease activity scores for TregPMA

53 racteristics, YAC84Q mice showed a rescue of body weight loss and extended survival upon calpain-1 kn

54 ment delayed the onset of motor symptoms and body weight loss and extended the survival of HD mice.

55 he lowest severity of infection, assessed by body weight loss and food intake.

56 al disease, including its vicious cycle with body weight loss and heavier infection with malnutrition

57 PINTA745 reduced body weight loss and improved body weight recovery after

58 Paroxetine attenuated motor dysfunction and body weight loss and improved glucose metabolism in the

59 on while maintaining reduced food intake and body weight loss and improved glucose tolerance.

60 ions when orally dosed in mice and prevented body weight loss and improved inflammatory and fibrotic

61 The CaM-fragment significantly reduced body weight loss and improved motor function as indicate

62 farction, respectively, along with decreased body weight loss and improved neurological function as c

63 containing the muropeptide precursor reduces body weight loss and improves histological parameters in

64 dy-treated group by week 9, with significant body weight loss and increased bacterial load in the lun

65 (P<0.05) reduction of neurological deficits, body weight loss and infarct volume (22.8+/-2.1%) withou

66 resulted in a reduction in infection-induced body weight loss and inflammation and significantly incr

67 h as acting as an antimicrobial, stimulating body weight loss and interfering with the toxicity of pr

68 -/-) mice developed dramatically exacerbated body weight loss and intestinal pathology, but they surp

69 or (GLP-1R) results in glycemic lowering and body weight loss and is a therapeutic strategy to treat

70 also been found to reduce radiation-induced body weight loss and lethality in mouse models.

71 , where GcgR activation failed to induce the body weight loss and lipid metabolism changes observed i

72 296 significantly improves survival, reduces body weight loss and lung viral titers, and prevents lun

73 ined locomotor impairment in the open field, body weight loss and metabolic alterations measured by i

74 S.C. mAb35 administration induced body weight loss and MG symptoms comparable to I.P. admi

75 d and lung pathology, in addition to reduced body weight loss and mortality.

76 ng the AM depletion phase caused significant body weight loss and mortality.

77 tor (+)-JQ1 protects tumor-bearing mice from body weight loss and muscle and adipose tissue wasting.

78 taxis, reduce lung virus titers, and prevent body weight loss and pulmonary inflammation.

79 its ability to inhibit dexamethasone-induced body weight loss and systemic hypertension in rats.

80 gnificant weight loss (60% percent of excess body weight loss) and resolution (83%) of T2DM.

81 trated by undetectable viral titers, lack of body weight loss, and a significant reduction in the lev

82 O mice causes suppression of food intake and body weight loss, and decreased food intake is primarily

83 a systemic inflammatory state, an increased body weight loss, and failed to induce neutralizing anti

84 tion, while maintaining reduced food intake, body weight loss, and improved glucose tolerance.

85 ificantly lowered lung viral titers, reduced body weight loss, and improved survival rates after leth

86 replication in the lungs, prevented dramatic body weight loss, and increased survival rates of mice i

87 th antibiotics reduced microorganism growth, body weight loss, and mortality but had no effect on ves

88 reatment with adelmidrol decreased diarrhea, body weight loss, and myeloperoxidase activity.

89 Infarct volume, body weight loss, and neurological deficit were measured

90 ce exhibited higher bacterial burden, severe body weight loss, and pathological changes after Chlamyd

91 lungs of IAV-infected mice, alleviated their body weight loss, and prolonged their survival.

92 treatment resulted in decreased food intake, body weight loss, and reduced adiposity at doses that pr

93 observed that IL-22 induces thymic atrophy, body weight loss, and renal proximal tubule metabolic ac

94 perative complications, percentage of excess body weight loss, and time to return to activities of da

95 Severe body weight loss as high as 20-25% was observed which wa

96 ge heart rate, plasma lactate concentration, body weight loss as well as post-game sprint performance

97 Excess body weight loss at 1 year was 13% lower for SG (60%) th

98 Excess body weight loss at 1 year; resolution of medical comorb

99 five percent of patients achieved >20% total body weight loss at 18 months post-BS, with a mean diffe

100 Cox regression showed that percent body weight loss at 24 hours predicted death by 48 hours

101 The SG cohort sustained higher % total body weight loss at 3 years post-LT (28.9% vs. 5.4%, p <

102 Body weight loss at 6 weeks and 3 months postoperatively

103 The mean excess body weight loss at time of second biopsy was 59% +/- 22

104 s a multifactorial syndrome characterized by body weight loss, atrophy of adipose tissue (AT) and sys

105 vere microbiota-dependent gut tissue damage, body weight loss, bacterial translocation and gut dysbio

106 Again, these effects were not secondary to body weight loss, because food restricted rats had the s

107 The 1.2% ARG HD group showed reduced body weight loss, better motor functioning, and fewer ch

108 ificant differences in the percent of excess body weight loss between the 2 groups at the 3-year foll

109 tory of complicated delivery, percent excess body weight loss, BMI, type of weight loss procedure and

110 uine herpesvirus 1 (EHV-1) displayed reduced body weight loss but had higher pulmonary viral loads.

111 w flutters, head shakes, diarrhea, and total body weight loss), but did not elicit any cannabimimetic

112 e abrogated the CREBH-mediated reductions in body weight loss, but only partially reversed the observ

113 acy and reduced toxicity as measured by mean body weight loss (BWL) in vivo [body weight loss of 7.7

114 s against cancer-induced cardiac atrophy and body weight loss by signaling through its receptor.

115 cisplatin/CA4/PhB (85%) while displaying <5% body weight loss compared to cisplatin (20%) or CA4 (10%

116 g replication in lungs and nasal turbinates, body weight loss, cytokine storm, and lung pathology.

117 ut altering LPS-induced sickness measured by body weight loss, decreased motor activity, and reduced

118 ected Plscr1(-/-) mice exhibited exacerbated body weight loss, decreased survival rates, heightened v

119 ange during a 3-month period) with an excess body weight loss (defined using body mass index threshol

120 ermates that was evaluated by survival rate, body weight loss, diarrhea and fecal blood score, and hi

121 cancer-related death that causes progressive body weight loss due to depletion of skeletal muscle mas

122 diabetic rats restored euglycemia, minimized body weight loss due to food restriction, substantially

123 partially mediates the lower food intake and body weight loss during chemotherapy treatment.

124 -wk low-calorie diet (LCD) resulting in >=8% body weight loss, during which changes in body compositi

125 s, decrease in BMI, and percentage of excess body weight loss (% EBWL) after surgery.

126 IL-1 and IL-6 in mediating the anorexic and body weight loss effects of GLP-1 receptor activation.

127 igated stress-induced ROS/RNS production and body weight loss even prior to colitis onset, reduced co

128 olic surgery who had experienced 20% or less body weight loss from the day of surgery and a suboptima

129 cted the bone marrow cells and prevented the body weight loss from the effect of irradiation, and fac

130 In the training set of 61 patients, excess body weight loss >95% (odds ratio [OR] 6.73, 95% confide

131 Mice expressing mutant huntingtin show body weight loss, have motor function deficits, and die

132 Body weight loss, hepatocyte infection frequency, viral

133 ira, which was followed by urinary shedding, body weight loss, hypothermia, and colonization of the k

134 We found that 4b significantly prevented body weight loss, improved several parameters of motor f

135 studies have shown that apart from inducing body weight loss, improving cardiometabolic parameters,

136 ation developed symptoms of cachexia such as body weight loss in a time- and dose-dependent manner.

137 de attenuates cisplatin-induced anorexia and body weight loss in addition to pica, demonstrating that

138 2a (YSH6000) resulted in diarrhea and severe body weight loss in adult B6 mice.

139 vivo (S.C., 10 nmol/kg QD) and showed potent body weight loss in diet-induced obese mice and a half-l

140 le obese mice, but did not affect CL-induced body weight loss in male or female obese mice.

141 ury, and elevated levels are associated with body weight loss in numerous chronic human diseases.

142 d 73% of tumor growth delay without apparent body weight loss in the murine CT26 syngeneic model, aft

143 potential to mitigate decreased appetite and body weight loss in the setting of anorexia or cachexia

144 There was no significant body-weight loss in any group.

145 uten-dependent enteropathy (in model 3), and body weight loss (in model 3).

146 cardiorespiratory responses, hypothermia and body weight loss) in rats that received 5 or 10 injectio

147 s) vs 15.9% excess weight loss (6.0% initial body weight loss) in the sham group.

148 biological activity attenuated anorexia and body weight loss induced by central exendin-4 administra

149 rtin receptors 3/4 reversed the anorexia and body weight loss induced by TLR2 activation.

150 During prolonged cold, however, the body weight loss is attenuated, caused by adaptive mecha

151 ant to Lm infection, with significantly less body weight loss, less Lm burden in liver and spleen, an

152 rapeutic agent-induced toxicities, including body weight loss, lethality, neurotoxicity, and hematoto

153 0 mg/kg daily o.s.) was able to decrease the body weight loss, macroscopic damage, colon length, hist

154 not differ between the injection sites, but body weight loss measured 24 h after lateral-i.c.v. inje

155 ypes than the original BACHD mice, including body weight loss, movement deficits, robust striatal neu

156 velop a progressive disease characterized by body weight loss, muscle weakness, brain atrophy, and mo

157 Body weight loss of >= 10% improves the metabolic derang

158 cess body weight loss of 25% to 60% or total body weight loss of 10% to 20% for sleeve gastrectomy, R

159 xia models induced a more rapid and profound body weight loss of 15.4%.

160 nduced obese mice resulted in a lean-sparing body weight loss of 20% over 1 mo, statistically the sam

161 y correct adjustable gastric band and excess body weight loss of 25% to 60% or total body weight loss

162 I of 34.07 +/- 3.73 kg/m, representing total body weight loss of 25.13 +/- 4.44% and excess weight lo

163 ble for a subset and suggested median excess body weight loss of 31%-61%.

164 ndex threshold of 25) of 25% to 40% or total body weight loss of 5% to 12% for anatomically correct a

165 ured by mean body weight loss (BWL) in vivo [body weight loss of 7.7 +/- 4% vs. 18 +/- 5% for Dtxl-NP

166 describe salivary microbiome changes during body weight loss on an individual-specific level, and to

167 preoperative requirements were met: 7% total body weight loss or 6 months of counseling and no weight

168 on than free DOX without causing significant body weight loss or cardiotoxicity.

169 ed the survival of mice with no irreversible body weight loss or hematopoietic damage.

170 ated suppression of FGF21 was independent of body weight loss or improved hepatic insulin sensitivity

171 rmittent or daily schedule in the absence of body weight loss or Notch-related toxicities.

172 results in reduced energy intake and greater body weight loss over time when compared to chronic mono

173 in HD mice accelerated the time of onset of body weight loss (P<0.05) and motor impairments (P<0.05)

174 sion of Fah-positive hepatocytes rescued the body weight loss phenotype.

175 cation in mice and these mice display faster body weight loss, poorer survival, and a greater degree

176 FL118 induced favorable body-weight-loss profiles (temporary and reversible) and

177 Compared to young mice, delayed body weight-loss recovery and a lag in polycythemic resp

178 at among the DIRECT-PLUS participants, 1% of body weight loss resulted in an 8.9 months' attenuation

179 ns attenuated cisplatin-induced anorexia and body weight loss significantly.

180 ns attenuated cisplatin-induced anorexia and body weight loss significantly.

181 in supplementation occurred after an initial body weight loss similar to what we previously reported

182 stration from 5 to 11 weeks of age prevented body weight loss, skeletal muscle atrophy, muscle weakne

183 Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study.

184 Total body weight loss (TBWL) is an important approach, as its

185 The primary endpoint was 6-month total body weight loss (TBWL).

186 Main outcomes were the percentage of total body weight loss (%TBWL) and HRQOL (Impact of Weight on

187 OMP, CpG, and alum showed significantly less body weight loss than the corresponding control mice imm

188 t physiological mechanisms to defend against body weight loss, they have only weak physiological mech

189 unds evaluated in the model, CpG-ODN reduced body weight loss (to <6% on days 3-7 after challenge), r

190 rcentage of patients who achieved >20% total body weight loss up to 18 months post-BS.

191 y fourth day) to induce an approximately 15% body weight loss, upon which they were randomized to con

192 4% excess weight loss (9.2% of their initial body weight loss) vs 15.9% excess weight loss (6.0% init

193 At week 16, the mean body weight loss was 15.4 kg (95% CI, 12.3-18.5 kg; P <

194 Body weight loss was doubled in knockout (28%) and wa-1

195 VID-HIGIV treated animals, infection-related body weight loss was reduced and the animals regained th

196 RSV-induced clinical illness and body weight loss were also reduced by BHA treatment, whi

197 However, anemia and body weight loss were partially prevented, tissue cell a

198 n1a(Pax8/LC1)) that exhibit hyperkalemia and body weight loss when kept on a regular-salt diet, thus

199 eductions in tumor burden with minimal total body weight loss when treated with L-377, 202.

200 o mice, the 11SB17 strain causes only slight body weight loss, whereas 11SB23 produces acute and leth

201 duces dextran sulfate sodium colitis-induced body weight loss, which is accompanied by reduced expres

202 tion, reduced serum BA levels, and prevented body weight loss, while improving markers of liver injur

203 ents with advanced cancers and causes severe body weight loss, with rapid depletion of skeletal muscl

204 as that dose that produces a maximum 12-15% body weight loss within 2 weeks after a single i.v. inje

205 PACAP dose-dependently induced anorexia and body weight loss without affecting locomotor activity.